Human IL2RA (CD25): A Dual-Role Target Shaping the Future of Immunotherapy

Concept: Human IL2RA (CD25) – The Linchpin of IL-2 Signaling and Immune Homeostasis

Interleukin-2 receptor alpha chain (IL2RA), commonly known as CD25, is a pivotal transmembrane glycoprotein and the rate-limiting subunit of the high-affinity interleukin-2 (IL-2) receptor complex. This complex is tripartite, consisting of IL2RA (α chain), IL2RB (β chain), and IL2RG (γc chain)—a shared common gamma chain across multiple cytokine receptors. Notably, IL2RA alone exhibits only low-affinity binding to IL-2 and lacks a functional intracellular signaling domain; its core biological role lies in forming a high-affinity receptor complex with IL2RB and IL2RG, enhancing cellular sensitivity to IL-2 by over 100-fold. As a "molecular gatekeeper" of IL-2 signaling, IL2RA dictates the threshold and intensity of immune cell responses to IL-2, a cytokine central to T cell proliferation, differentiation, survival, and functional modulation. Its selective expression on regulatory T cells (Tregs) and aberrant expression on certain tumor cells position IL2RA as a dual-faced target in immunotherapy—simultaneously mediating immune tolerance and tumor immune evasion, making it a focal point of research in oncology, autoimmunity, and transplantation immunology.

Research Frontiers of IL2RA in Immunotherapy

The field of IL2RA research is evolving at a rapid pace, with cutting-edge investigations focusing on unraveling its context-dependent functions and translating these insights into next-generation immunotherapeutic strategies. A core research frontier is the precise dissection of IL2RA’s dual roles in immune regulation: its indispensable role in maintaining Treg-mediated immune tolerance (critical for preventing autoimmunity) and its pro-tumorigenic role in enabling Treg-driven immunosuppression in the tumor microenvironment (TME) and supporting tumor cell proliferation. Contemporary studies are leveraging single-cell sequencing and spatial transcriptomics to map IL2RA expression patterns across immune cell subsets and tumor types, revealing tissue-specific and disease-stage-specific expression dynamics that could inform personalized therapeutic strategies.

Another key research direction is the development of selective IL2RA-targeting therapeutics that overcome the limitations of first-generation agents. Traditional anti-CD25 antibodies exhibit poor selectivity, depleting both immunosuppressive Tregs and activated effector T cells (which transiently upregulate CD25 during clonal expansion), leading to compromised antitumor immunity and increased infection risk. Next-generation strategies focus on enhancing target selectivity—for example, developing conditionally activated antibodies that only bind IL2RA in the IL-2-rich TME, or engineering antibodies that recognize conformational or glycosylation-specific variants of IL2RA uniquely expressed on Tregs or tumor cells. Additionally, research is exploring combination therapies that pair IL2RA-targeting agents with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) or adoptive T cell therapies to synergistically reverse TME immunosuppression and amplify antitumor immune responses.

Research Significance of IL2RA Study

Unraveling the complex biology of IL2RA and developing advanced tools for its study hold profound scientific and translational significance for immunology research and clinical medicine.

In basic immunology research, IL2RA serves as a key model for understanding cytokine receptor signaling and immune cell cross-talk. Studies of IL2RA’s role in Treg development, homeostasis, and suppressive function deepen our understanding of immune tolerance mechanisms, addressing fundamental questions about how the immune system balances self-tolerance and pathogen defense. Furthermore, investigating IL2RA’s aberrant expression on tumor cells provides insights into tumor immune evasion strategies, shedding light on the molecular basis of immunosuppressive TME formation.

Translationally, IL2RA has emerged as a versatile therapeutic target and prognostic biomarker. In oncology, high Treg infiltration and IL2RA expression in the TME correlate with poor patient prognosis across multiple cancer types, making IL2RA a potential predictive biomarker for immunotherapy response. Targeting IL2RA to deplete Tregs or block tumor cell IL-2 signaling represents a promising strategy to enhance antitumor immunity, with several anti-CD25 antibodies and antibody-drug conjugates (ADCs) currently in clinical trials. In autoimmunity and transplantation, IL2RA-targeting agents are used to suppress overactive immune responses, preventing autoimmune disease progression and transplant rejection. For the biopharmaceutical industry, IL2RA research drives the development of novel biologics, including selective Treg-depleting agents, IL-2/IL2RA complex agonists, and tumor-specific anti-CD25 ADCs, while creating demand for high-quality research tools to validate these therapeutic approaches.

Mechanisms, Regulatory Functions and Product Applications

Core Mechanisms of IL2RA-Mediated Immune Regulation and Tumor Progression

IL2RA in IL-2 Signaling and Immune Cell Modulation

IL2RA exerts its biological effects primarily through mediating IL-2 signaling, a pathway central to immune cell homeostasis and function:

1. High-affinity receptor complex formation: IL2RA (α chain) binds IL-2 with low affinity, but upon association with IL2RB (β chain) and IL2RG (γc chain), forms a high-affinity receptor complex that enables efficient IL-2 signaling even at picomolar concentrations. This complex recruits Janus kinases (JAKs) to the intracellular domains of IL2RB and IL2RG, triggering JAK phosphorylation and subsequent activation of downstream signaling cascades—including JAK-STAT, PI3K-Akt-mTOR, and Ras-MAPK pathways.
2. Treg function and immune tolerance: Tregs constitutively express high levels of IL2RA, 赋予 them a competitive advantage in sequestering limited IL-2 in the TME. This IL-2 "scavenging" restricts IL-2 availability for effector T cells (Teffs), inhibiting their proliferation and activation—a key mechanism of Treg-mediated immune suppression. Additionally, IL-2 signaling through IL2RA is essential for Treg development in the thymus, peripheral homeostasis, and maintenance of their suppressive function, highlighting IL2RA’s non-redundant role in immune tolerance.
3. Effector T cell activation: Activated Teffs transiently upregulate IL2RA during the early phase of immune responses, enabling them to respond to IL-2 produced by T cell receptor (TCR) engagement and costimulation. This IL-2/IL2RA signaling drives Teff clonal expansion, differentiation into memory cells, and acquisition of effector functions (e.g., cytokine secretion, cytotoxicity), underscoring IL2RA’s dual role in promoting both immune tolerance and adaptive immunity.

IL2RA in Tumor Immune Evasion and Progression

Beyond its role in immune cells, IL2RA contributes to tumor progression through two key mechanisms:

1. Tumor cell-autonomous signaling: IL2RA is aberrantly expressed on the surface of various hematologic malignancies (e.g., leukemia, lymphoma) and solid tumors (e.g., renal cell carcinoma, melanoma). In these contexts, IL2RA may form functional receptors (either as part of the tripartite complex or alternative complexes) that transduce IL-2 signals to drive tumor cell proliferation, survival, and resistance to chemotherapy or immunotherapy.
2. Soluble IL2RA (sCD25)-mediated immune suppression: Tumor cells or infiltrating immune cells in the TME can shed soluble IL2RA (sCD25) into the circulation or local microenvironment. sCD25 binds circulating IL-2, neutralizing its bioactivity and reducing its availability for Teffs; it may also compete with membrane-bound IL2RA for IL-2 binding, disrupting normal immune surveillance. Elevated serum sCD25 levels correlate with poor prognosis in multiple cancers, serving as a potential prognostic biomarker and therapeutic target.

Key Application Scenarios of IL2RA Research and ANT BIO PTE. LTD. Products

High-quality recombinant IL2RA protein is an indispensable tool for advancing IL2RA-related research and therapeutic development. ANT BIO PTE. LTD.’s Human IL2RA, His Tag (Catalog No.: S0A4006)—developed under the UA sub-brand, specialized in high-purity, bioactive recombinant proteins—exhibits superior bioactivity, ultra-high purity, and exceptional stability, making it ideal for a wide range of research applications.

Core Advantages of ANT BIO PTE. LTD.’s Human IL2RA, His Tag (S0A4006)

表格

Key Application Scenarios for S0A4006 Human IL2RA, His Tag

1. Immune Signaling Pathway Research: Investigate the molecular mechanisms of IL-2/IL2RA signaling, including receptor complex assembly (IL2RA-IL2RB-IL2RG), JAK-STAT pathway activation, and downstream modulation of Treg homeostasis and Teff proliferation.
2. Drug Discovery and High-Throughput Screening: Serve as a key target protein for screening and evaluating IL2RA-targeting therapeutics, including neutralizing antibodies, agonists, antagonists, and ADCs. Enable the development of in vitro binding assays (e.g., ELISA, SPR) to quantify drug-target interaction affinity and specificity.
3. Diagnostic Reagent Development: Act as a standard reference or coating antigen for the development of sCD25 detection kits (e.g., ELISA, chemiluminescence), facilitating immune monitoring in autoimmune diseases, transplantation, and hematologic malignancies.
4. Protein Interaction and Complex Studies: Characterize the binding kinetics between IL2RA and IL-2, as well as interactions with other receptor subunits (IL2RB, IL2RG) or novel regulatory proteins, using techniques such as Co-IP, pull-down assays, and cryo-EM.
5. Tumor Immunology and TME Research: Study the role of IL2RA in Treg-mediated immunosuppression in the TME; evaluate the impact of IL2RA-targeting agents on Treg depletion and Teff activation using in vitro TME models.
6. Autoimmunity and Transplantation Research: Investigate IL2RA’s role in autoimmune disease pathogenesis (e.g., multiple sclerosis, rheumatoid arthritis) and evaluate IL2RA-targeting agents for suppressing pathogenic immune responses in preclinical models.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.